Cronos Group Inc vs MasterCard Inc — how do they compare? Cronos Group Inc trades at $3.08 (market cap $1.11B), while MasterCard Inc trades at $561.9 (market cap $493.34B). The key difference: MasterCard Inc is far larger — about 444.5× Cronos Group Inc's market cap, and MasterCard Inc pays a 0.62% dividend while Cronos Group Inc pays none. Which is the better fit depends on your goals.
| CRON | MA | |
|---|---|---|
Market Cap | $1.11B | $493.34B |
Sector | Health | Consumer Cyclical |
52-Week High | $3.27 | $598.96 |
52-Week Low | $2.30 | $471.55 |
Enterprise Value | $310.67M | $506.38B |
Volume | — | 4,635,698 |
Dividend Yield | — | 0.62% |
Signals from Pluang's Aura AI — not financial advice
CRON trades at $3.10 with a 0.98% daily gain, showing bullish technical momentum. The company delivered strong Q2 2026 results with 58% YoY revenue growth and earnings beat, while maintaining #1 market share in Canadian vapes and edibles. Despite negative net income in 2025, revenue growth accelerated to $147M with improving margins. Technical indicators show bullish moving averages but RSI suggests potential overbought conditions near $3 resistance.
Outlook remains positive with international expansion and European cannabis legalization driving growth, though competitive pressures and execution risks persist. Analyst consensus is mixed with 60% hold ratings, reflecting cautious optimism about CRON's turnaround trajectory from previous losses to projected 39% profit margin by 2026.
Mastercard (MA) trades at $563.17, up 0.04% on the day, with a bullish technical signal supported by moving averages and strong institutional buying interest. The company continues to deliver robust financial performance, with Q2 2026 EPS of $5.04 beating estimates of $4.77, marking the third consecutive quarterly beat. Revenue growth remains strong, rising from $22.2B in 2022 to $32.8B in 2025, while maintaining net income margins above 45%. Recent news highlights Mastercard's expansion into AI-driven payments and initiatives to connect underbanked populations.
The outlook for MA remains positive given its consistent earnings beats, high profitability, and dominant market position. However, investors should monitor competitive threats from emerging payment technologies like stablecoins and regulatory scrutiny. With 79% analyst buy ratings and a consensus price target of $660.85, Wall Street sees approximately 17% upside potential from current levels.
Trailing returns across standard periods
Latest headlines on both assets
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →